Industry News/Treatment

Research Agreement To Develop Clotrimazole for Sickle Cell Anemia

Published in Blood Weekly, July 24th, 1995

Sheffield Medical Technologies Inc., New York, New York, announced that it has entered into an option and sponsored research agreement with Children's Hospital, Boston, Massachusetts, to develop clotrimazole and its metabolites for the treatment of sickle cell anemia.

The option includes exclusive rights to an issued U.S. patent covering clotrimazole for this use, as well as rights to data from preclinical and pilot clinical studies conducted to date.

Clotrimazole has a long history of use in humans as an antifungal agent. The rationale for using clotrimazole to treat sickle cell anemia is based on its ability to prevent the dehydration of red blood...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1995-07-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry